Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004900 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer
A Phase 2 study, sponsored by Hackensack Meridian Health.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00004900 is a Phase 2 study that has completed, run by Hackensack Meridian Health.
The verdict
NCT00004900, a Phase 2 study, has completed, sponsored by Hackensack Meridian Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy plus peripheral stem cell transplantation in treating women who have metastatic breast cancer.
Interventions
- DRUG cisplatin
- DRUG carboplatin
- DRUG cyclophosphamide
- DRUG anastrozole
- BIOLOGICAL filgrastim
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-10 |
| Est. Completion | 2004-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004900
The ClinicalTrials.gov registry entry for NCT00004900 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00004900 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004900 about?
NCT00004900 is a clinical study titled "Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial...
What is the current status of trial NCT00004900?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-10. Estimated completion is 2004-08.
What interventions are being tested in trial NCT00004900?
The interventions under investigation include: cisplatin (DRUG), carboplatin (DRUG), cyclophosphamide (DRUG), anastrozole (DRUG), filgrastim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00004900?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.